A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This is an open-label, randomised, multicenter, Mircera-controlled, parallel-group, Phase III
study to determine whether subcutaneous administered efepoetin alfa is as effective and well
tolerated as subcutaneous Mircera for anaemia correction and maintenance in erythropoiesis
stimulating agent (ESA)-naïve subjects who have CKD and are not on dialysis. ESA prior users
who have stopped using ESA at least 12 weeks till screening will also be eligible for this
study provided they fulfil all the subject entry criteria.